期刊文献+

人脑胶质瘤中尿激酶型纤溶酶原激活物受体的表达与临床病理分级的关系

The relation between the expression of urokinase-type plasminogen activator receptor and clinical pathologic grade in human brain glioma
暂未订购
导出
摘要 目的 探讨尿激酶型纤溶酶原激活物受体 (u PAR)在人脑胶质瘤中的表达及其与临床病理分级的关系。方法 应用流式细胞仪定量检测 35例标本中u PAR含量 ,其中I级 8例 ,II级 9例 ,III级 9例 ,IV级 6例 ,正常脑组织 3例 ,染色应用直接染色法。结果 u PAR在人脑胶质瘤中的表达与病理分级相关 ,III级、IV级与I级、II级和正常脑组织相比较 ,差异有极显著的统计学意义 ,P值均小于 0 0 1。III级与IV级相比较 ,P <0 0 1;I级与II级相比较 ,P >0 0 5 ,差异没有统计学意义。结论 u PAR表达与病理分级相关 (r=0 83) ,可作为判断人脑胶质瘤恶性程度和浸润性能的指标。 Objective: To investigate the pathologic significance of quantitation of urokinase type plasminogen activator receptor in human brain glioma. Methods: The specimens of 35 cases were quantitated by flow cytometry (FCM), including grade I 8, grade II 9, grade III 9, grade IV 6,and 3 normal brain tissues. Direct staining was used in this study. Results: The intensity of individual u PAR expression in human glioma was correlated with the pathologic grade, and quantitative assay showed that u PAR expression was higher in grade III and grade IV than that in grade I, grade II and normal brain. There was significant differences between them (P<0 01). The expression in grade IV was higher than that in grade III (P<0 01), and there was no significant difference between grade I and grade II (P>0 05). Conclusion: The expression of u PAR is positively correlated with the pathologic grade or pattern (r=0 83), and the expression of u PAR can be the index of judging the malignant degree and infiltrative ability.
出处 《泰山医学院学报》 CAS 2001年第3期202-205,共4页 Journal of Taishan Medical College
关键词 纤溶酶原激活物 尿激酶型 脑胶质瘤 病理学 流式细胞术 plasminogen activator urokinase type receptor glioma pathology flow cytometry
  • 相关文献

参考文献27

  • 1[1]Abaza MS,ShabanFA, NaRAyan RK, etal. In vitro inhibition of human malignant brain tumor cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies[J]. Br J Cancer, 1998, 78(2): 1578-1585.
  • 2[2]Mohanam S, Sawaya R, McCutcheon I, et al. Modulation of in vitro of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody [J ]. Cancer Res, 1993, 53: 4143-4147.
  • 3[3]Schmitt M, Wilhelm O, Janicke F, et al. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis[J ]. J Obstet Gynaecol. 1995, 21(2): 151-65.
  • 4[4]Bruckner A, Filderman AE, Kirchheimer JC, et al. Endogenous receptor-bound urokinase mdiates tissue invasion of the human lung carcinoma cell line A549 and Calu-1[J]. Cancer Res, 1992,52: 3043-3047.
  • 5[5]Olson D, PollanenJ, Hoyer-HansenG, etal. Intemalization of the urokinase plasminogen activator inhibitor type-1 comples is mediated bythe urokinse receptor[J]. J Biol chem., 1992, 267: 9129-.9133.
  • 6[6]Hudson MA, McReynold LM. Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines[J]. AdvExp Med Biol, 1999, 462: 399-412.
  • 7[7]Foekens PA, PetersHA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 brdast cancer patients [J]. Cancer Res, 2000, 60: 636-643.
  • 8[8]OkusaY, IchikuraT, Mochizuki H, et al. Urokinase type plesminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines[J]. InJ Oncol, 2000, 17(5): 1001-1005.
  • 9[9]Morita-Y, Hayashi-Y, Wang-Y, et al. Expression of urokinasetype plasmincgen activator receptor in hepatocellular carcinoma [J]. Hepatology, 1997, 25(4): 856-861.
  • 10[10]Morita-S, Sato-A, Hayakawa-H, et al. Cancer cells overexpress mRNA of urokinase-type plasminogen actvator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysisby Nothem blotting and in situ hybridization [J ]. Int J Cancer, 1998, 78(3): 286-292.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部